GYRE
Gyre Therapeutics, Inc.
GYRE has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GYRE overall, supported by stronger fundamentals and stronger modeled upside.
GYRE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
GYRE's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GYRE PE Valuation
GYRE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GYRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect GYRE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over GYRE on the outlook, with more favorable earnings and revenue expectations.
GYRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.05 | +$2.86 |
| Q3 2024 | -$1.26 | +$19.44 |
| Q2 2024 | -$1.87 | +$20.63 |
| Q1 2024 | -$2.93 | -193% |
| Q4 2023 | -$2.81 | +$1.09 |
| Q3 2023 | -$20.70 | -463% |
| Q2 2023 | -$22.50 | -$18.60 |
| Q1 2023 | $3.15 | +$41.25 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 114% for GYRE versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GYRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $32.9M | +7.8% |
| Q2 2026 | $29.1M | +8.7% |
| Q1 2026 | $22.5M | +2.1% |
| Q4 2025 | $37.2M | +33% |
| Q3 2025 | $30.6M | +20% |
| Q2 2025 | $26.8M | +6.1% |
| Q1 2025 | $22.1M | -19% |
| Q1 2022 | $794K | -46% |
GYRE's revenue has grown year over year for six quarters in a row: $33M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | -27 points |
| Q2 2026 | -49% | -58 points |
| Q1 2026 | -42% | -52 points |
| Q4 2025 | 0.3% | -1.8 points |
| Q3 2025 | 23% | +6.1 points |
| Q2 2025 | 8.1% | -4.8 points |
| Q1 2025 | 10% | -19 points |
| Q4 2024 | 2.1% | N/A |
GYRE's operating margin was −4.6% last quarter, down 27 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GYRE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over GYRE on profitability, with a higher operating margin.
GYRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | -224% |
| Q2 2026 | -$17M | -1027% |
| Q1 2026 | $3M | +$3.3M |
| Q4 2025 | -$5.8M | -$3.1M |
| Q3 2025 | $4M | +288% |
| Q2 2025 | $1.8M | +$8.8M |
| Q1 2025 | -$251K | -109% |
| Q3 2024 | $1M | +$4.3M |
GYRE has burned cash in most quarters: −$25M over the past year, against $3M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GYRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GYRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +5.7M shares |
| 1 year | +2.2% | +2.3M shares |
| 3 years | +4955% | +104M shares |
| 5 years | +7124% | +105M shares |
GYRE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GYRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -15.1x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
| Q1 2023 | -1.3x | Net Cash |
| Q3 2022 | -2.0x | Net Cash |
GYRE has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GYRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 10.3 | Oversold |
GYRE's weekly RSI is 32 (neutral) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GYRE PE vs Healthcare Sector
| Metric | GYRE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GYRE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GYRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.88 | 27% below |
| 20 week MA | $6.33 | 32% below |
| 50 week MA | $6.89 | 38% below |
| 100 week MA | $7.91 | 46% below |
| 200 week MA | $9.42 | 54% below |
GYRE is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over GYRE on trend strength, trading above more of its moving averages.
GYRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.4 | $97.1 | -4.3% |
| 2021 | $97.1 | $15.9 | -84% |
| 2022 | $15.9 | $7.50 | -53% |
| 2023 | $7.50 | $25.7 | +243% |
| 2024 | $25.7 | $12.5 | -52% |
| 2025 | $12.5 | $7.26 | -42% |
| 2026 YTD | $7.26 | $4.30 | -41% |
GYRE's yearly returns have swung widely, from +243% in 2023 to −84% in 2021. It's down 41% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GYRE on returns for 2026, with the stronger performance.